As shown in Supplementary Table 2, no significant differences in age, hemoglobin, lymphocyte count, prothrombin time(PT), tumor markers after the third cycle of chemotherapy, or the preoperative platelet to postoperative platelet ratio (defined as the preoperative platelet count divided by the platelet count after three cycles of primary adjuvant chemotherapy) were noted among the 171 EOC cases with thrombocytosis and non-thrombocytosis. This evidence concerns the gene F2 and neoplasm.